Julie C. Sung

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Julie

Last Name

Sung

NPI

1235660168

Faculty ID

19430

CMO Specialties

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

123336

Is Open Scheduling

Off

Melanie A. Hundt

https://assets.montefioreeinstein.org/profiles/images/Hundt_Melanie_MD_2x.jpg

First Name

Melanie

Last Name

Hundt

NPI

1659861144

Faculty ID

18274

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

202066

Biography

<p>Melanie A. Hundt, MD, is an attending physician at Montefiore Einstein. Dr. Hundt specializes in providing care for people with advanced liver disease, including individuals who may require a liver transplant. Dr. Hundt is passionate about increasing access to liver specialty care and transplantation.</p><p>After earning her Doctor of Medicine at the State University of New York Upstate Medical University in 2018, Dr. Hundt completed her residency at Yale New Haven Hospital in 2021. She then completed a gastroenterology fellowship and a transplant hepatology fellowship at the University of Southern California in 2024.</p><p>She has shared her work through numerous peer-reviewed publications and presentations.</p><p>Dr. Hundt is board certified in Internal Medicine. She is a member of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG) and the American Association for the Study of Liver Diseases (AASLD), among others. Dr. Hundt is fluent in English and Spanish.</p>

Is Open Scheduling

Off

Rebecca S. Roediger

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3c699940-848e-11ee-9baf-47fb58c10652.jpg

First Name

Rebecca

Last Name

Roediger

NPI

1790102747

Faculty ID

17849

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

188728

Biography

<p>Rebecca Roediger, MD, is an attending physician at Montefiore Einstein. Her clinical focus centers on transplant hepatology, alcohol-associated liver disease and viral hepatitis.</p><p>After obtaining her Bachelor of Arts in psychology from Stanford University in 2008, Dr. Roediger earned her Doctor of Medicine at Weill Cornell Medical College in 2014. She completed her internal medicine residency at Mount Sinai Hospital in 2017, followed by a gastroenterology fellowship at Washington University in 2020. Dr. Roediger then completed a gastroenterology transplant hepatology fellowship at the same institution in 2021.</p><p>Dr. Roediger&rsquo;s research focus is on the treatment and outcomes of alcohol-associated liver disease. She is also interested in global health and liver disease. Her work has been shared through numerous peer-reviewed publications and presentations.</p><p>Dr. Roediger is board certified by the American Board of Internal Medicine.</p>

Is Open Scheduling

Off

Alexander S. Vogel

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/7bae2f70-7c8d-11ee-9139-01bda7ad7f9a.jpg

First Name

Alexander

Last Name

Vogel

NPI

1942695077

Faculty ID

17791

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

188603

Biography

<p>Alexander S. Vogel, MD, is a transplant hepatologist at Montefiore Einstein and Assistant Professor, Medicine at our Albert Einstein College of Medicine. He also serves as the Associate Program Director for the transplant hepatology fellowship. Dr. Vogel specializes in the treatment of patients with advanced liver disease and liver cancer and managing patients both before and after liver transplantation. He believes strongly in patient-centered care with a focus on respect and close communication. Dr. Vogel is committed to educating his patients on their medical conditions to help empower them.</p><p>After obtaining a Bachelor of Arts from Brown University, Dr. Vogel earned his Doctor of Medicine from the Icahn School of Medicine at Mount Sinai in 2015. He then completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai in 2018 and served as Chief Resident the following year. Following this, he completed a gastroenterology, hepatology and endoscopy fellowship at Brigham and Women&rsquo;s Hospital in 2022 before pursuing his advanced fellowship training in transplant hepatology at the Icahn School of Medicine at Mount Sinai in 2023, where he was Chief Fellow.</p><p>Dr. Vogel's research interests include alcohol-associated liver disease, health literacy, and health disparities with a focus on improved access to specialized liver care and liver transplantation. As a passionate medical educator, Dr. Vogel also works to improve the training experience for medical students, residents and fellows through curricular development and direct training experiences. His work has been shared through numerous peer-reviewed publications and invited presentations nationally.</p><p>Dr. Vogel is board certified by the American Board of Internal Medicine in Gastroenterology and Internal Medicine. He is a member of several professional societies, including the American Association for the Study of Liver Disease (AASLD), the American Society of Transplantation (AST) and the Gold Humanism Society, among others. In 2021, Dr. Vogel was selected for the American College of Gastroenterology Young Physician Leadership Scholars Program, and in 2022, he was awarded an AASLD Advanced/Transplant Hepatology Award.</p>

Is Open Scheduling

Off

Clara Y. Tow

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tow_Clara_MD_420x504.jpg

First Name

Clara

Last Name

Tow

NPI

1174822845

Faculty ID

15844

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tow is a transplant hepatologist and Assistant Professor of Medicine at Montefiore Medical Center and Albert Einstein College of Medicine. She serves as the Clinical Site Director of Hepatology at the Weiler Division of MMC, Associate Program Director of the Gastroenterology &amp; Liver Diseases Fellowship Program, and the Co-Director of the AECOM Gastroenterology &amp; Hepatology Systems Course.</p>
<p>Dr. Tow holds a B.A. in Biological Sciences from Cornell University College of Arts and Sciences and graduated Phi Beta Kappa and Magna Cum Laude for her work in developmental research. While attending Weill Cornell Medical College, she developed her passion for transplant medicine and was awarded Alpha Omega Alpha and Honors in Research for her characterization of mitochondrial injury during ischemia-reperfusion injury. Dr. Tow completed her internship and residency in Internal Medicine at New York Presbyterian Hospital - Weill Cornell Medical Center, where she served as an education resident, and fellowship in Gastroenterology and Liver Diseases at Montefiore Medical Center. Subsequently she pursued her advanced fellowship training in Transplant Hepatology at New York Presbyterian Hospital &ndash; Columbia University Medical Center.</p>
<p>Dr. Tow has been at Montefiore/Einstein since 2018, where she specializes on the complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore family and that patient knowledge is power. Her goal is to provide patients and their families the best medical care that is embedded in kindness, dignity, and respect.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity, and respect.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles, and abstracts.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

29458

Biography

<p>Clara Y. Tow, MD, is Clinical Site Director, Hepatology, Associate Program Director, Gastroenterology &amp; Liver Diseases Fellowship Program, Co-Course Director, Gastroenterology &amp; Hepatology Systems Course and Assistant Professor, Medicine at Montefiore Einstein. Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity and respect.</p><p>After obtaining her Bachelor of Arts in biological sciences from Cornell University College of Arts and Sciences, Dr. Tow earned her Doctor of Medicine from Weill Cornell Medical College. She then completed her internship and residency in internal medicine at NewYork-Presbyterian Hospital, Weill Cornell Medical Center. Following this, she completed a gastroenterology and liver diseases fellowship at Montefiore Medical Center before pursuing her advanced fellowship training in transplant hepatology at NewYork-Presbyterian Hospital.</p><p>Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Tow is board certified by the American Board of Internal Medicine in transplant hepatology, gastroenterology and internal medicine. She is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation (AST) and the European Association for the Study of the Liver (EASL). She is also a member of the Empire Liver Foundation and a Medical Advisor for the American Liver Foundation. In 2014, Dr. Tow won the Erica C. Jones &amp; Naina Sinha-Gregory Prize in Medicine.</p>

Is Open Scheduling

On

Jonathan M. Schwartz

https://assets.montefioreeinstein.org/profiles/images/Schwartz_Jonathan_MD_2x.jpg

First Name

Jonathan

Last Name

Schwartz

NPI

1215945738

Faculty ID

648

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. &nbsp;He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. &nbsp;He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. &nbsp;Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL.&nbsp; High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV.&nbsp; Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, &nbsp;Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O&rsquo;Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma.&nbsp; Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1,&nbsp;<strong>Schwartz JM,</strong>&nbsp;Martel-Laferriere V,&nbsp;Giannattasio ER,&nbsp;Marfo K,&nbsp;Odin JA,&nbsp;Liu LU,&nbsp;Schiano TD,&nbsp;Perumalswami P,&nbsp;Bansal M,&nbsp;Gaglio PJ,&nbsp;Kalia H,Dieterich DT,&nbsp;Branch AD,&nbsp;Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther.&nbsp;2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL.&nbsp; Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma.&nbsp; In Rose BD, editor. Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr.&nbsp; Clinical features, diagnosis, and screening for primary hepatocellular carcinoma.&nbsp; Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr.&nbsp; Nonsurgical therapies for localized hepatocellular carcinoma.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.<strong>&nbsp;</strong></li>
<li><strong>Schwartz JM</strong>.&nbsp; Approach to the patient with a focal liver lesion.&nbsp; Up to date Inc Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM.&nbsp; </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF.&nbsp; Prevalence and Natural History of Alcoholic Liver Disease.&nbsp; Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p>&nbsp;</p>

EMR ID

3842

Is Open Scheduling

Off

John F. Reinus

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/af2bc270-3a87-11ed-8158-59ecbd24247c.jpg

First Name

John

Last Name

Reinus

NPI

1669557435

Faculty ID

2404

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<FONT color=#000000>Clinical practice limited to liver diseases.&nbsp; Research on liver diseases and related topics.</FONT>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

Selected Publications

<p>&nbsp;</p>
<ol>
<li>Gaglio P, Moss N, McGaw C, Reinus JF. Direct-acting antiviral therapy for hepatitis C: Attitudes regarding future use. Dig Dis Sci. 2011; 56:1509-1515.</li>
<li>Flattau A, Olaywi M, Gaglio PJ, Marcus P, Meissner P, L Dorfman EB, Reinus JF. Social barriers to listing for adult liver transplantation: Their prevalence and association with program characteristics. Liver Transpl. 2011; 17:1167-1175.</li>
<li>Golowa YS, Cynamon J, Reinus JF, Kinkhabwala M, Abrams M, Jagust M, Chernyak V, Kaubisch A. Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads. J Vasc Interv Radiol. 2012; 23:1031-1035.</li>
<li>Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis. 2012; 16:659-666. Review.</li>
<li>Kinkhabwala M, Lindower J, Reinus JF, Principe AL, Gaglio PJ. Expedited liver allocation in the United States: a critical analysis. Liver Transpl. 2013; 19: 1159-1165.</li>
<li>Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther. 2014; 39:209-216.</li>
<li>Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF. Limited fibrosis progression but significant mortality in patients ineligible for interferon-based hepatitis C therapy.&nbsp; J Clin Exp Hepatol. 2016 Jun;6(2):100-8.</li>
<li>Chacko KR, Reinus J.&nbsp; Spectrum of alcoholic liver disease.&nbsp; Clin Liver Dis. 2016 Aug;20(3):419-27.</li>
<li>Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease.&nbsp; Clin Liver Dis. 2016 May;20(2):387-401. Review.</li>
</ol>
<p>&nbsp;</p>

EMR ID

3634

Biography

<p>John F. Reinus, MD, is Emeritus Medical Director, Liver Transplantation and Professor, Medicine at Montefiore Einstein. His work centers on liver transplantation, end-stage liver disease and viral hepatitis.</p><p>Dr. Reinus studied Pre-Medical Sciences at Columbia University before earning his Doctor of Medicine at Cornell Medical College in 1981. He then began an internal medicine internship at Bellevue Hospital Center, completing it in 1982. Following this, Dr. Reinus completed a residency in internal medicine at the same institution in 1984 before completing a hepatology fellowship at Emory University School of Medicine in 1985. He went on to complete a fellowship in gastroenterology at the same institution, finishing it in 1987. Dr. Reinus then completed a Transplant Hepatology Preceptorship at the Center for Liver Disease and Transplantation in 2006.</p><p>Building on his clinical focus, Dr. Reinus&rsquo; research is focused on liver diseases and related topics. His work has been published in peer-reviewed journals, books, chapters, reviews and abstracts, and he has presented at numerous conferences and meetings.</p><p>Dr. Reinus is board certified by the American Board of Medical Examiners in Internal Medicine, Gastroenterology and Transplant Hepatology. He is a fellow of the American Association for the Study of Liver Diseases and a member of the American Gastroenterological Association and the American Society of Transplantation.</p>

Is Open Scheduling

Off

Brett E. Fortune

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/bd026af0-c49b-11ec-b83c-ebcf060bac15.jpeg

First Name

Brett

Last Name

Fortune

NPI

1720121585

Faculty ID

17475

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Brett E. Fortune, MD, MSc, is Medical Director, Liver Transplant Program, and Associate Professor, Medicine at Montefiore Einstein. His clinical focus centers on providing care for patients with advanced liver disease and those who need or have received liver transplantation.</p>
<p>After obtaining his Bachelor of Science in biological sciences in 1999 from North Carolina State University, Dr. Fortune earned his Doctor of Medicine from Wake Forest University School of Medicine in 2004. He then completed an internship and residency in internal medicine at The Ohio State University Medical Center in 2007. After this, he participated in a gastroenterology fellowship at the University of Colorado Denver, where he also earned his Master of Science in clinical sciences, completing both in 2011. Dr. Fortune remained there for another year to participate in a transplant hepatology fellowship, which he completed in 2012.</p>
<p>Dr. Fortune&rsquo;s research focuses on clinical outcomes related to cirrhosis and portal hypertension complications as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant. His work has been published in numerous peer-reviewed journals or books. He is currently Associate Editor for Liver Transplantation and Liver Section Editor for Digestive Disease Interventions, and has sat on the editorial board for Hepatology.</p>
<p>Dr. Fortune is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology by the American Board of Internal Medicine. He is a member of many professional organizations, such as the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterology Association (AGA) and the American Liver Foundation. Dr. Fortune won the Kushlan Junior Faculty Award, Section of Digestive Diseases in 2015 and the Howard M. Spiro Digestive Disease Fellowship Teaching Award in 2016 from Yale School of Medicine.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

P1004568

Biography

<p>Brett E. Fortune, MD, MSc, is Medical Director, Liver Transplant Program, and Associate Professor, Medicine at Montefiore Einstein. His clinical focus centers on providing care for patients with advanced liver disease and those who need or have received liver transplantation.</p><p>After obtaining his Bachelor of Science in biological sciences in 1999 from North Carolina State University, Dr. Fortune earned his Doctor of Medicine from Wake Forest University School of Medicine in 2004. He then completed an internship and residency in internal medicine at The Ohio State University Medical Center in 2007. After this, he participated in a gastroenterology fellowship at the University of Colorado Denver, where he also earned his Master of Science in clinical sciences, completing both in 2011. Dr. Fortune remained there for another year to participate in a transplant hepatology fellowship, which he completed in 2012.</p><p>Dr. Fortune&rsquo;s research focuses on clinical outcomes related to cirrhosis and portal hypertension complications as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant. His work has been published in numerous peer-reviewed journals or books. He is currently Associate Editor for <em>Liver Transplantation</em> and Liver Section Editor for <em>Digestive Disease Interventions</em>, and has sat on the editorial board for <em>Hepatology</em>.</p><p>Dr. Fortune is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology by the American Board of Internal Medicine. He is a member of many professional organizations, such as the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterology Association (AGA) and the American Liver Foundation. Dr. Fortune won the Kushlan Junior Faculty Award, Section of Digestive Diseases in 2015 and the Howard M. Spiro Digestive Disease Fellowship Teaching Award in 2016 from Yale School of Medicine.</p>

Is Open Scheduling

Off

Kristina R. Chacko

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/34425bb0-e66a-11ee-bf98-11b627c2384b.jpg

First Name

Kristina

Last Name

Chacko

NPI

1528246097

Faculty ID

13632

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Kristina R. Chacko, MD, is an Associate Professor of Medicine at the Albert Einstein College of Medicine in Bronx, NY. &nbsp;She joined the Einstein-Montefiore Liver Center in 2013 after completing a fellowship in Transplant Hepatology at Mount Sinai School of Medicine in New York, NY. &nbsp;She received her bachelor of arts in philosophy at Boston College and attended medical school at Baylor College of Medicine in Houston, TX. &nbsp;She completed her internal medicine residency at Emory University in Atlanta, GA, and gastroenterology fellowship at New York University.&nbsp;&nbsp;Her clinical and research interests include the diagnosis and management of alcoholic hepatitis, non-alcoholic fatty liver disease, autoimmune liver diseases, and liver transplantation.&nbsp; As the program director of the ACGME-accredited transplant hepatology fellowship at Montefiore Medical Center, she is directly involved in the development and execution of the hepatology curriculum for gastroenterology and hepatology fellows.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p><span style="color:#616161;font-family:'SF Pro Text', 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif, Roboto;font-size:14px;letter-spacing:-0.24px;background-color:#f5f5f5;">Transplant Hepatology, Autoimmune Hepatitis, Fatty Liver Disease (Alcohol/Non-alcohol), Acute alcoholic hepatitis, Living Donor Transplant</span></p>

Research Focus

<span style="color:#616161;font-family:'SF Pro Text', 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif, Roboto;font-size:14px;letter-spacing:-0.24px;background-color:#f5f5f5;">Research interest includes alcohol-related liver disease, liver transplantation, viral hepatitis and autoimmune liver disease.</span>

Elsevier Profile

Selected Publications

<p style="text-align: left;"><span style="color: #222222; font-family: Arial, sans-serif; font-size: 13px;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Nahas J, Tow CY, <strong>Chacko KR</strong>, Haider T, Massoumi H. Granulocyte colony-stimulating factor does not improve mortality in severe alcoholic hepatitis: a single-center experience from the United States. Gastroenterol Hepatol Bed Bench. 2023;16(1):524-526. PMID: 37070107</span></span></p>
<p style="text-align: left;"><span style="color: #222222; font-family: Arial, sans-serif; font-size: 13px;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">D&iacute;az LA, Fuentes-L&oacute;pez E, Ayares G, Idalsoaga F, Arnold J, Valverde MA, Perez D, G&oacute;mez J, Escarate R, Villal&oacute;n A, Ram&iacute;rez CA, Hernandez-Tejero M, Zhang W, Qian S, Simonetto DA, Ahn JC, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, Garc&iacute;a-Carrera I, Cuy&agrave;s B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni AV, Rao PN, Salazar PG, Skladan&yacute; L, Bystrianska N, Clemente-Sanchez A, Villaseca-G&oacute;mez C, Haider T, <strong>Chacko KR</strong>, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Marciano S, Dirchwolf M, Vargas V, Jim&eacute;nez C, Louvet A, Garc&iacute;a-Tsao G, Roblero JP, Abraldes JG, Shah VH, Kamath PS, Arrese M, Singal AK, Bataller R, Arab JP. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Rep. 2023 Mar 15;5(8):100727. PMID: 37456675;&nbsp;</span></span></p>
<p style="text-align: left;"><span style="color: #222222; font-family: Arial, sans-serif; font-size: 13px;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Arab JP, D&iacute;az LA, Baeza N, Idalsoaga F, Fuentes-L&oacute;pez E, Arnold J, Ram&iacute;rez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, Zhang W, Clark V, Simonetto D, Ahn JC, Buryska S, Mehta TI, Stefanescu H, Horhat A, Bumbu A, Dunn W, Attar B, Agrawal R, Haque ZS, Majeed M, Cabezas J, Garc&iacute;a-Carrera I, Parker R, Cuy&agrave;s B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de la Tijera MF, Kulkarni AV, Rao PN, Guerra Salazar P, Skladan&yacute; L, Bystrianska N, Prado V, Clemente-Sanchez A, Rinc&oacute;n D, Haider T, <strong>Chacko KR</strong>, Cairo F, de Sousa Coelho M, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Narvaez A, Bessone F, Marcelo JS, Piombino D, Dirchwolf M, Arancibia JP, Altamirano J, Kim W, Araujo RC, Duarte-Rojo A, Vargas V, Rautou PE, Issoufaly T, Zamarripa F, Torre A, Lucey MR, Mathurin P, Louvet A, Garc&iacute;a-Tsao G, Gonz&aacute;lez JA, Verna E, Brown RS, Roblero JP, Abraldes JG, Arrese M, Shah VH, Kamath PS, Singal AK, Bataller R. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021 Nov;75(5):1026-1033. doi: 10.1016/j.jhep.2021.06.019. Epub 2021 Jun 21. PMID: 34166722.</span></span></p>
<p style="text-align: left;"><span style="color: #222222; font-family: Arial, sans-serif; font-size: 13px;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Andacoglu O, &Ouml;zbek U, Liu J, Figueredo C, <strong>Chacko KR</strong>, Tow C, Reinus JF, Kinkhabwala M. Comparison of 1-Year Morbidity Following Liver Transplant for Acute Alcoholic Hepatitis Versus Alcoholic Cirrhosis. Exp Clin Transplant. 2021 May;19(5):439-444. Epub 2021 Jan 11. PMID: 33455569.</span></span></p>
<p style="text-align: left;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londo&ntilde;o MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016 Apr;22(4):446-58. PMID: 26890629.</span></p>
<p style="text-align: left;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Chacko KR</strong>, Wolkoff AW. Intrahepatic Cholestasis of Pregnancy: New Diagnostic Insights. Ann Hepatol. 2017 March-April;16(2):176-178.&nbsp; PMID: 28233755.</span></p>
<p style="text-align: left;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Chacko KR</strong>, Reinus J. Spectrum of Alcoholic Liver Disease. Clin Liver Dis. 2016 Aug;20(3):419-27. doi: 10.1016/j.cld.2016.02.002. Epub 2016 May 31. PMID: 27373606.</span></p>
<p style="text-align: left;"><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Chacko KR</strong>, Reinus J. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016 May;20(2):387-401. doi: 10.1016/j.cld.2015.10.004. Epub 2016 Feb 18. PMID: 27063276.</span></p>

EMR ID

5713

Is Open Scheduling

On